Bipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms, functional impairment, psychosocial disability and diminished well-being. More recent data have underlined the importance of neurocognitive impairments in the euthymic state including impairments in attention, memory and executive function.
Conditions
Interventions
Sponsors
Department of Psychiatry and Psychotherapy, Charity University Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Bipolar Disorder (BP I + BP II) Ethymic mood state since 6 months at least Stable medication with mood stabilizers Age > 18 y. Cognitive Impairment measured on self reporting questionnaires Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Axis 1 condition other than bipolar disorder during last 6 month organic brain disorder pregnancy or breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To improve baseline cognitive functioning regarding verbal memory by 12 weeks aripiprazole add-on therapy in bipolar, euthymic patients. ;Secondary Objective: Secondary endpoints are the changes in cognitive functioning in the following domains: 1. working memory 2. executive functioning 3. attention ;Primary end point(s): Primary endpoint is change in verbal memory function measured with California Verbal Learning Test (CVLT). | — |
Countries
Germany
Outcome results
None listed